Scout Investments Inc. raised its stake in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 64.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 840,017 shares of the specialty pharmaceutical company’s stock after purchasing an additional 327,870 shares during the quarter. Scout Investments Inc.’s holdings in Supernus Pharmaceuticals were worth $27,905,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. State of Alaska Department of Revenue lifted its stake in shares of Supernus Pharmaceuticals by 2.6% in the 4th quarter. State of Alaska Department of Revenue now owns 17,506 shares of the specialty pharmaceutical company’s stock worth $581,000 after purchasing an additional 447 shares during the period. First Republic Investment Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 10.3% in the 2nd quarter. First Republic Investment Management Inc. now owns 12,572 shares of the specialty pharmaceutical company’s stock worth $753,000 after purchasing an additional 1,179 shares during the period. Oppenheimer Asset Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 9.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock worth $746,000 after purchasing an additional 1,251 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of Supernus Pharmaceuticals by 13.8% in the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 12,465 shares of the specialty pharmaceutical company’s stock worth $628,000 after purchasing an additional 1,509 shares during the period. Finally, Raymond James & Associates lifted its stake in shares of Supernus Pharmaceuticals by 17.8% in the 2nd quarter. Raymond James & Associates now owns 10,319 shares of the specialty pharmaceutical company’s stock worth $618,000 after purchasing an additional 1,557 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Supernus Pharmaceuticals stock traded up $1.77 during midday trading on Friday, hitting $37.72. The stock had a trading volume of 612,076 shares, compared to its average volume of 550,467. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 29.94, a P/E/G ratio of 0.90 and a beta of 1.34. Supernus Pharmaceuticals Inc has a 52-week low of $30.05 and a 52-week high of $61.25. The company has a current ratio of 2.82, a quick ratio of 2.65 and a debt-to-equity ratio of 0.77.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.09. The company had revenue of $102.99 million during the quarter, compared to analyst estimates of $100.75 million. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.29 EPS. On average, analysts predict that Supernus Pharmaceuticals Inc will post 1.84 EPS for the current year.

SUPN has been the topic of several recent research reports. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, October 30th. Cantor Fitzgerald set a $56.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 22nd. ValuEngine upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. Mizuho started coverage on shares of Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating and a $61.00 target price for the company. Finally, B. Riley reduced their target price on shares of Supernus Pharmaceuticals from $68.00 to $65.00 and set a “buy” rating for the company in a report on Monday, November 12th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Supernus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $58.50.

TRADEMARK VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://theolympiareport.com/2019/01/11/supernus-pharmaceuticals-inc-supn-shares-bought-by-scout-investments-inc.html.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Read More: How to Track your Portfolio in Google Finance

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.